Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

BACKGROUND: Lung cancer is one of the most frequent cancer types and the leading cause of cancer death worldwide. Cisplatin is a widely used chemotherapeutic for non-small cell lung carcinoma (NSCLC), however, its positive effects are diminished under hypoxia. We wanted to determine if co-treatment...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer
Hlavní autoři: Fischer, Carina, Leithner, Katharina, Wohlkoenig, Christoph, Quehenberger, Franz, Bertsch, Alexandra, Olschewski, Andrea, Olschewski, Horst, Hrzenjak, Andelko
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4320451/
https://ncbi.nlm.nih.gov/pubmed/25608569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-14-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky